BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 728K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

22 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Thalidomide analogs and PDE4 inhibition.EBI
Celgene
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.EBI
Celgene
Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223.EBI
Celgene
Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.EBI
Celgene
Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.EBI
Celgene
Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury.EBI
Celgene
Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.EBI
Celgene
Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.EBI
Celgene
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.EBI
Celgene
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.EBI
Celgene
Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.EBI
Celgene
Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.EBI
Celgene
Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity.EBI
Celgene
1,1-Diarylalkenes as anticancer agents: dual inhibitors of tubulin polymerization and phosphodiesterase 4.EBI
Celgene
Structure-based design and discovery of potent and selective KDM5 inhibitors.EBI
Celgene
The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.EBI
Celgene
Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).EBI
Celgene
Pyrrolopyrimidine derivatives as TAM inhibitorsBDB
Incyte
Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5BDB
Vanderbilt University
Substituted aminopyrimidine compounds and methods of useBDB
Calitor Sciences
Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicamentsBDB
Bayer Intellectual Property
Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles.BDB
Wyeth Research